Chyawanprash

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: immunity energy longevity

Research Overview

Across the abstracts, research on Chyawanprash (CP) is most concentrated in three areas: (1) its traditional positioning and formulation science (multi-herb “rasayana”/rejuvenative jam, commonly ~50 ingredients), (2) immune and respiratory health claims assessed through clinical and observational literature reviews, and (3) ingredient-focused phytochemical/pharmacological work on constituent herbs used in CP (e.g., Leptadenia reticulata), including conservation and propagation issues relevant to supply and standardization. In parallel, COVID-19–era publications include survey-based reports describing public use of CP and other home remedies as perceived “immunity boosters,” but these primarily capture attitudes and self-reported behaviors rather than clinical efficacy against viral infection.

The strongest evidence in the provided set comes from a large randomized, open-label, prospective study in healthy schoolchildren (5–12 years) over 6 months, where daily CP (≈6 g) plus milk was associated with fewer episodes and reduced burden of infection/allergy-related illness compared with milk alone, alongside improvements in parent-reported energy, fitness, stamina, and quality-of-life scores. Collectively, the critical and ethnopharmacological reviews converge on a consistent signal that regular CP consumption over a defined period may improve general health status and reduce susceptibility to common illnesses, aligning with traditional claims; however, they also emphasize that much of the clinical literature is heterogeneous, often small, and of limited duration. Evidence cited for antiviral relevance in the COVID-19 context is indirect (e.g., plausibility from herbs/spices and survey perceptions) rather than demonstrating CP-specific prevention or treatment effects for SARS-CoV-2.

Key gaps highlighted include the need for higher-quality randomized controlled trials with adequate blinding where feasible, larger sample sizes, longer follow-up, and standardized CP formulations to address variability across commercial products. Future studies should incorporate contemporary, objective biomarkers of immune function and inflammation (pre/post), clinically adjudicated respiratory outcomes, and rigorous safety monitoring, including interactions when used as an adjunct to conventional therapies (e.g., anti-tubercular drugs, where historical interest exists). Additional research is also needed on ingredient-level mechanisms, identification of active compounds beyond crude extracts, and quality-control/standardization challenges linked to threatened medicinal plants (e.g., L. reticulata), which can affect reproducibility and generalizability of clinical findings.

1. What conditions has Chyawanprash been studied for?

  • Immunity-related illnesses in generally healthy children (episodes of infections and allergy-related conditions) in a 6‑month randomized, open-label clinical study in schoolchildren aged 5–12.

  • Pulmonary tuberculosis (PTB) as an adjunct to standard anti-tubercular drugs (ATDs), studied over 28 days in a clinical study that combined Chyawanprash with ashwagandha alongside ATDs.

  • Immune cell function (preclinical/in vitro): dendritic cell cytokine secretion (TNF‑α, IL‑1β, MIP‑1α), macrophage phagocytosis, and natural killer (NK) cell activity in laboratory assays.

  • Memory impairment / Alzheimer’s disease–relevant models (preclinical): mouse models of amnesia and memory deficits (including scopolamine- and alprazolam-induced amnesia), with associated oxidative stress markers and acetylcholinesterase activity.

  • COVID-19-era “immunity boosting” use (survey data): a questionnaire-based online survey reported that many respondents used Chyawanprash for immunity during COVID-19; this is not a treatment trial.

  • Broad non-communicable diseases (NCDs) and communicable diseases (CDs): a protocol for a systematic review (2010–2023 RCTs) indicates planned evaluation across multiple conditions, but does not itself provide results.

2. Does it work in treating those conditions? Summarize the evidence.

  • Healthy children (infection/allergy episodes): In a 6‑month, randomized, open-label study (702 randomized; 627 completed), the Chyawanprash group reportedly had “more than 2 times protection” from immunity-related illness versus control (milk only), and improvements in energy/fitness/stamina and quality of life. Limitations from the abstract include open-label design and reliance on parent-recorded diaries for illness outcomes.

  • Pulmonary tuberculosis (adjunct use): In 99 PTB patients receiving ATDs plus adjunct therapy (ashwagandha and a multi-herbal formulation described as Chyawanprash), the abstract reports symptom improvement, weight gain, ESR normalization, changes in IgA/IgM patterns, and increased bioavailability of isoniazid and pyrazinamide after 28 days. However, because the adjunct included both ashwagandha and Chyawanprash, the abstract does not allow attribution of effects to Chyawanprash alone, and the short follow-up limits conclusions about clinical endpoints (e.g., cure/relapse).

  • Immune mechanisms (in vitro): At non-cytotoxic concentrations (20–500 μg/ml), Chyawanprash increased dendritic-cell cytokines (TNF‑α, IL‑1β, MIP‑1α) and stimulated macrophage and NK cell activity in vitro. This supports biological plausibility for immunostimulation, but in vitro findings do not establish clinical effectiveness.

  • Memory/Alzheimer’s-relevant outcomes (animal models): In mice fed Chyawanprash (1–2% w/w of diet) for 15 days, the abstract reports protection against memory impairment across multiple maze tests and drug-induced amnesia models, with reduced TBARS and increased glutathione (GSH), suggesting antioxidant effects. These are preclinical results and cannot confirm benefit in humans with cognitive impairment.

  • COVID-19: The survey abstract reports that people used Chyawanprash and believed spices/herbs help against viral infections, but this is perception and usage data—not evidence that Chyawanprash treats or prevents COVID-19.

  • Overall evidence quality (from reviews): Two review abstracts emphasize that while published clinical studies suggest improvements in “overall health status and immunity,” much of the clinical literature is limited by small sample sizes, short duration, and limited availability/indexing; they call for higher-quality, larger, longer RCTs with modern immune biomarkers.

3. What health benefits does it have?

  • Reduced frequency/impact of common illnesses in children (clinical): The pediatric randomized study reports fewer immunity-related illness episodes (infections/allergy-related conditions), fewer/severity/duration-related improvements (as assessed in diaries), and fewer absent days due to illness (as an outcome category assessed).

  • Improved quality of life and perceived physical functioning in children (clinical): Better improvements in energy, physical fitness, strength, stamina, and quality of life (KIDSCREEN QOL‑27) were reported with 6 months of use.

  • Immunostimulatory activity at the cellular level (preclinical): Increased cytokine secretion from dendritic cells and increased macrophage and NK cell activity in vitro, consistent with immune activation.

  • Adjunctive support in PTB treatment (clinical, adjunct): In the PTB adjunct study, improvements were reported in symptoms, weight, ESR, immunoglobulin patterns (IgA/IgM), and increased blood levels (bioavailability) of isoniazid and pyrazinamide—suggesting potential supportive effects alongside ATDs (not proven as a standalone therapy).

  • Antioxidant and neurocognitive signals in animals (preclinical): Reduced oxidative stress markers (TBARS) and increased glutathione with improved performance in memory models, suggesting antioxidant and possible pro-cholinergic/anti-amnesic effects in mice.

  • Traditional/claimed benefits noted in reviews: Reviews describe traditional use for respiratory health, immune strengthening, prevention of recurrence of infections, and anti-inflammatory/antioxidant properties, while also noting that clinical substantiation is still limited.

4. Does it have any downsides or side effects?

  • Side effects were not rigorously characterized in the provided abstracts. The pediatric clinical abstract reports benefits but does not describe adverse event rates in the excerpt provided.

  • Perception data (not safety evidence): In the COVID-19 home-remedy survey, 86.1% of respondents believed kadha had no side effects and 13.9% believed it did; this does not establish actual safety for Chyawanprash specifically, nor does it replace adverse-event monitoring.

  • Potential for herb–drug interaction (signal from PTB study): The PTB adjunct study reported significantly increased bioavailability of isoniazid and pyrazinamide when ATDs were given with adjunct Ayurvedic therapy including Chyawanprash. While this could be beneficial, it also implies a possibility of altered drug exposure, which in other contexts could increase side effects or require monitoring. The abstract does not report toxicity outcomes in detail beyond mentioning assessed labs (LFTs, creatinine, blood sugar).

  • Evidence gaps highlighted by reviews: Review abstracts emphasize the need for higher-quality trials and modern biomarker-based assessments; this indirectly indicates that safety evidence (especially long-term, in diverse populations, and across brands/formulations) is not yet robustly established from the summarized literature.

Practical limitation from the abstracts: “Chyawanprash” is a multi-herb formulation and commercial products vary; the abstracts do not address batch standardization, which can affect both efficacy and tolerability.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not report pharmacogenomic analyses or genotype-stratified outcomes for Chyawanprash.

  • No direct evidence is presented linking Chyawanprash response or adverse effects to specific genetic variants (e.g., drug-metabolizing enzymes, immune genes).

  • The PTB adjunct study’s finding of increased isoniazid/pyrazinamide bioavailability suggests a plausible interaction with drug metabolism/transport pathways, but no genetic data (e.g., NAT2 acetylator status for isoniazid) are provided, so pharmacogenomic implications cannot be concluded from these abstracts.

References

  1. Chyawanprash: A Traditional Indian Bioactive Health Supplement.
    Rohit Sharma, Natália Martins, Kamil Kuca, Ashun Chaudhary, Atul Kabra, Meda M Rao, Pradeep Kumar Prajapati (2019) - Biomolecules
  2. Spices and herbs: Potential antiviral preventives and immunity boosters during COVID-19.
    Namita Ashish Singh, Pradeep Kumar, Jyoti, Naresh Kumar (2021) - Phytotherapy research : PTR
  3. Leptadenia reticulata (Retz.) Wight & Arn. (Jivanti): Botanical, Agronomical, Phytochemical, Pharmacological, and Biotechnological Aspects
    Sudipta Kumar Mohanty, Mallappa Kumara Swamy, Uma Rani Sinniah, Maniyam Anuradha (2017)
  4. Golden Ager Chyawanprash with Meager Evidential Base from Human Clinical Trials.
    Rohit Sharma, Pradnya Kakodkar, Atul Kabra, Pradeep Kumar Prajapati (2022) - Evidence-based complementary and alternative medicine : eCAM
  5. Evaluation of Cyavanaprāśa on Health and Immunity related Parameters in Healthy Children: A Two Arm, Randomized, Open Labeled, Prospective, Multicenter, Clinical Study.
    Arun Gupta, Sunil Kumar, Sanjeeva Dole, Shailesh Deshpande, Vaishali Deshpande, Sudha Singh, V Sasibhushan (2017) - Ancient science of life
  6. Chyawanprash: A review of therapeutic benefits as in authoritative texts and documented clinical literature.
    D B Anantha Narayana, Sharanbasappa Durg, P Ram Manohar, Anita Mahapatra, A R Aramya (2017) - Journal of ethnopharmacology
  7. Adjunct therapy of Ayurvedic medicine with anti tubercular drugs on the therapeutic management of pulmonary tuberculosis.
    P K Debnath, Jaydeb Chattopadhyay, Achintya Mitra, Anjan Adhikari, Mirza Samsur Alam, S K Bandopadhyay, Jayram Hazra (2012) - Journal of Ayurveda and integrative medicine
  8. Evaluation of immunostimulatory activity of Chyawanprash using in vitro assays.
    Alka Madaan, Satyajyoti Kanjilal, Arun Gupta, J L N Sastry, Ritu Verma, Anu T Singh, Manu Jaggi (2015) - Indian journal of experimental biology
  9. A comprehensive review on ayurvedic herb
    Sonali Kumari, Ravi Saini, Aditi Bhatnagar, Abha Mishra (2024) - Natural product research
  10. Antiamnesic activity of an ayurvedic formulation chyawanprash in mice.
    Milind Parle, Nitin Bansal (2011) - Evidence-based complementary and alternative medicine : eCAM
  11. An Ayurvedic Medication (Chyawanprash) as a Prophylaxis for Non-Communicable Disease and Communicable Disease: A Protocol for Systematic Review and Meta-Analysis.
    Shubham Sharma, Khushboo Kumari, Gayathree Sethuraman, Maya M Abdelwahab, Suhasini Sivaperumal Yadav, Vangala Nandini (2023) - Cureus
  12. In-silico modeling of the interplay between APOE4, NLRP3, and ACE2-SPIKE complex in neurodegeneration between Alzheimer and SARS-CoV: implications for understanding pathogenesis and developing therapeutic strategies.
    Sriranjini A S, Ashish Thapliyal, Kumud Pant (2024) - Journal of biomolecular structure & dynamics
  13. Beneficial effect of chyawanprash on cognitive function in aged mice.
    Nitin Bansal, Milind Parle (2011) - Pharmaceutical biology
  14. Prospective, Randomized, Open-Label, Blinded End Point, Two-Arm, Comparative Clinical Study to Evaluate the Efficacy and Safety of a Fixed Ayurvedic Regimen (FAR) as Add-on to Conventional Treatment in the Management of Mild and Moderate COVID-19 Patients.
    Arun Gupta, Sasibhushan Vedula, Ruchi Srivastava, Sanjay Tamoli, Narendra Mundhe, D N Wagh, Sanjay Batra, Manoj Patil, Hiren Baburao Pawar, Rajiva K Rai (2021) - Journal of pharmacy & bioallied sciences
  15. Chyawanprash, a formulation of traditional Ayurvedic medicine, shows a protective effect on skin photoaging in hairless mice.
    Yuki Takauji, Kyoko Morino, Kensuke Miki, Mohammad Hossain, Dai Ayusawa, Michihiko Fujii (2016) - Journal of integrative medicine
  16. Assembling cyavanaprāsh, Ayurveda's best-selling medicine.
    Maarten Bode (2015) - Anthropology & medicine
  17. Immunostimulant and chemoprotective effect of vivartana, a polyherbal formulation against cyclophosphamide induced toxicity in Swiss albino mice.
    Sadhana Gnanasekaran, Kunnathur Murugesan Sakthivel, Guruvayoorappan Chandrasekaran (2015) - Journal of experimental therapeutics & oncology
  18. Evaluation of anti-inflammatory and immunomodulatory activity of Chyawanprash on particulate matter-induced pulmonary disease in mice.
    Satyendra Kumar, Padmanabha Rugvedi, Kamaraj Mani, Arun Gupta (2021) - Journal of Ayurveda and integrative medicine
  19. Chyawanprash, An Ancient Indian Ayurvedic Medicinal Food, Regulates Immune Response in Zebrafish Model of Inflammation by Moderating Inflammatory Biomarkers.
    Acharya Balkrishna, Meenu Tomer, Moumita Manik, Jyotish Srivastava, Rishabh Dev, Swati Haldar, Anurag Varshney (2021) - Frontiers in pharmacology
  20. Exploring the viability of Zeatin as a prospective therapeutic candidate for investigating the complex interplay between severe acute respiratory syndrome coronavirus (SARS-CoV) and Alzheimer's disease.
    A S Sriranjini, Ashish Thapliyal, Kumud Pant (2024) - In silico pharmacology


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!